There was a significant trend for improved outcomes in patients with extrahepatic disease progression as opposed to liver only progression at the outset.
← all excerpts
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.
1
—
—